Healthcare
LeMaitre Vascular, Inc.(LMAT)
Live Price
Offline$93.95
+1.89% today
1Y Change
+11.13%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $2.54B
- Revenue Growth
- +13.5%
- EPS Growth
- +30.1%
- Dividend Yield
- 0.8%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LeMaitre Vascular, Inc. (LMAT) is a Healthcare stock with a market cap of $2.54B and listed on NASDAQ. The stock last traded around $93.95 and up 11.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +13.5%, EPS growth of +30.1%, a dividend yield of 0.8%. What stands out right now is revenue +13.5%, EPS +30.1%, free cash flow +100.4% with operating margin 27.2% and ROIC 9.0%. The dividend is present but secondary, with a yield around 0.8%. Valuation already assumes a fairly strong business story at P/E 43.9 and price/sales 10.2. Stock Foundry combines LMAT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.5% vs +7.6% peer median
Operating Margin
Above sector median
+27.2% vs +19.4% peer median
P/E
Above sector median
43.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +13.5% and EPS at +30.1%, with operating margin around 27.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.8%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | -7.8% | -12.4% |
2026 Feb 25, 2026 | +1.5% | +24.4% | +16.4% | +21.6% |
2025 Nov 6, 2025 | +9.9% | +1.4% | +4.7% | -1.2% |
Benchmark Edge
LMAT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LMAT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LMAT Max Drawdown
-22.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LMAT and SPY.
Company Overview
LeMaitre Vascular, Inc.
NASDAQ Global Market
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
- Leadership
- George W. LeMaitre
- IPO Date
- Oct 19, 2006
- Employees
- 651
- Street Address
- 63 Second Avenue
- Mailing
- Burlington, MA, 01803
- Region
- Burlington, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 221 2266
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 43.9
- EV/EBITDA
- 29.7
- Price/Sales
- 10.2
- Price/Book
- 6.4
Growth
- Revenue
- +13.5%
- EPS
- +30.1%
- Free Cash Flow
- +100.4%
Profitability
- Gross Margin
- 71.5%
- Operating Margin
- 27.2%
- Net Margin
- 23.1%
- ROE
- 15.6%
- ROIC
- 9.0%
Balance Sheet
- Debt/Equity
- 0.47
- Current Ratio
- 12.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.